Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
Data pulled from 1/1/2023
Converting Your Vial Into an Accurate, Measurable Dose A reference chart covering common CJC-1295 concentrations, U-100 syringe units, mL conversions, and reconstitution examples to help you understand your prescription
(Lausanne) 12 , 665537 (2021)
Injection site reactions: Localised redness, bruising, or discomfort at the subcutaneous injection site have been reported
These can include: Nausea Constipation Diarrhoea Vomiting Abdominal pain Fatigue Gastroesophageal reflux disease (GERD) Indigestion Be sure to inform your prescriber of any concerns or side effects you experience